C
지놈앤컴퍼니
314130KOSDAQ기초 의약물질 제조업49.5 / 100
Reference Date: 2026-04-13
Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure12.0 / 15
AI Analysis: PBR is undervalued vs. peers but ROE is below the industry average. Plunged 23.2% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Genom and Company aims to grow into a fully integrated pharmaceutical company by focusing on innovative drug development, utilizing its GNOCLE™ platform to advance pipeline candidates such as the immunotherapy GENA-104 and microbiome-based treatment GEN-001. The company also diversifies its business through CDMO services and its microbiome cosmetics brand 'UIQ'.
Number of Employees
96people
Average Salary
60.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 33.454.0Point
PBR
2.02Industry Average 2.034.0Point
In line with industry avg
ROE
-7.20Industry Average -4.293.5Point
1.7x industry avg (good)
Debt Ratio
6.62Industry Average 6.612.0Point
Higher than industry avg (caution)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲41.3% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲17.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -23.6% (improving, 3yr)
Detailed News Sentiment
6 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (55%)
Current 6,620Won52-week high 9,97052-week low 2,465
1-month return0.0Point
1m -23.20% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
10 totalPositive 1Neutral 9Negative 0
- Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-04-07
- Positive주요사항보고서(유상증자결정)2026-04-03
- Neutral주식매수선택권부여에관한신고2026-03-30
- Neutral주식매수선택권부여에관한신고2026-03-30
- Neutral정기주주총회결과2026-03-30